EdgarLookup

BECTON DICKINSON & CO — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that BECTON DICKINSON & CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
7.7%
Profit Margin
Net income ÷ revenue
3%
Return on Assets
Net income ÷ assets
+8.2%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $21.84B Nov 25, 2025
FY2025 Sep 30, 2024 $20.18B Nov 25, 2025
FY2025 Sep 30, 2023 $19.37B Nov 25, 2025
FY2024 Sep 30, 2022 $18.87B Nov 27, 2024
FY2023 Sep 30, 2021 $19.13B Nov 21, 2023
FY2020 Sep 30, 2020 $4.78B Nov 25, 2020
FY2020 Jun 30, 2020 $3.86B Nov 25, 2020
FY2020 Mar 31, 2020 $4.25B Nov 25, 2020
FY2020 Dec 31, 2019 $4.23B Nov 25, 2020
FY2020 Sep 30, 2019 $4.58B Nov 25, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Sep 30, 2017 $3.17B Nov 22, 2017
FY2017 Jun 30, 2017 $3.04B Nov 22, 2017
FY2017 Mar 31, 2017 $2.97B Nov 22, 2017
FY2017 Dec 31, 2016 $2.92B Nov 22, 2017
FY2017 Sep 30, 2016 $3.23B Nov 22, 2017
FY2017 Jun 30, 2016 $3.20B Nov 22, 2017
FY2017 Mar 31, 2016 $3.07B Nov 22, 2017
FY2017 Dec 31, 2015 $2.99B Nov 22, 2017
FY2016 Sep 30, 2015 $3.06B Nov 23, 2016
FY2016 Jun 30, 2015 $3.12B Nov 23, 2016

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2020 Sep 30, 2020 $2.21B Nov 25, 2020
FY2020 Jun 30, 2020 $1.66B Nov 25, 2020
FY2020 Mar 31, 2020 $1.73B Nov 25, 2020
FY2020 Dec 31, 2019 $1.98B Nov 25, 2020
FY2019 Sep 30, 2019 $2.27B Nov 27, 2019
FY2019 Jun 30, 2019 $2.07B Nov 27, 2019
FY2019 Mar 31, 2019 $1.97B Nov 27, 2019
FY2019 Dec 31, 2018 $1.97B Nov 27, 2019
FY2018 Sep 30, 2018 $2.09B Nov 21, 2018
FY2018 Jun 30, 2018 $2.02B Nov 21, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $1.68B Nov 25, 2025
FY2025 Sep 30, 2024 $1.71B Nov 25, 2025
FY2025 Sep 30, 2023 $1.48B Nov 25, 2025
FY2024 Sep 30, 2022 $1.78B Nov 27, 2024
FY2023 Sep 30, 2021 $2.09B Nov 21, 2023
FY2020 Sep 30, 2020 $128.00M Nov 25, 2020
FY2020 Jun 30, 2020 $286.00M Nov 25, 2020
FY2020 Mar 31, 2020 $183.00M Nov 25, 2020
FY2020 Dec 31, 2019 $278.00M Nov 25, 2020
FY2020 Sep 30, 2019 $163.00M Nov 25, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $2.58B Nov 25, 2025
FY2025 Sep 30, 2024 $2.40B Nov 25, 2025
FY2025 Sep 30, 2023 $2.11B Nov 25, 2025
FY2024 Sep 30, 2022 $2.28B Nov 27, 2024
FY2023 Sep 30, 2021 $2.25B Nov 21, 2023
FY2022 Sep 30, 2020 $912.00M Nov 22, 2022
FY2021 Sep 30, 2019 $1.76B Nov 24, 2021
FY2020 Sep 30, 2018 $1.51B Nov 25, 2020
FY2019 Sep 30, 2017 $1.52B Nov 27, 2019
FY2018 Sep 30, 2016 $1.43B Nov 21, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $1.27B Nov 25, 2025
FY2025 Sep 30, 2024 $1.19B Nov 25, 2025
FY2025 Sep 30, 2023 $1.24B Nov 25, 2025
FY2024 Sep 30, 2022 $1.26B Nov 27, 2024
FY2023 Sep 30, 2021 $1.28B Nov 21, 2023
FY2022 Sep 30, 2020 $1.04B Nov 22, 2022
FY2021 Sep 30, 2019 $1.06B Nov 24, 2021
FY2020 Sep 30, 2018 $1.00B Nov 25, 2020
FY2019 Sep 30, 2017 $770.00M Nov 27, 2019
FY2018 Sep 30, 2016 $828.00M Nov 21, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $5.28B Nov 25, 2025
FY2025 Sep 30, 2024 $4.86B Nov 25, 2025
FY2025 Sep 30, 2023 $4.72B Nov 25, 2025
FY2024 Sep 30, 2022 $4.71B Nov 27, 2024
FY2023 Sep 30, 2021 $4.72B Nov 21, 2023
FY2022 Sep 30, 2020 $4.19B Nov 22, 2022
FY2021 Sep 30, 2019 $4.33B Nov 24, 2021
FY2020 Sep 30, 2018 $4.02B Nov 25, 2020
FY2019 Sep 30, 2017 $2.91B Nov 27, 2019
FY2018 Sep 30, 2016 $3.01B Nov 21, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2021 Sep 30, 2021 $4.65B Nov 24, 2021
FY2021 Sep 30, 2020 $3.54B Nov 24, 2021
FY2021 Sep 30, 2019 $3.33B Nov 24, 2021
FY2020 Sep 30, 2018 $2.87B Nov 25, 2020
FY2019 Sep 30, 2017 $2.55B Nov 27, 2019
FY2018 Sep 30, 2016 $2.56B Nov 21, 2018
FY2017 Sep 30, 2015 $1.73B Nov 22, 2017
FY2016 Sep 30, 2014 $1.75B Nov 23, 2016

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $760.00M Nov 25, 2025
FY2025 Sep 30, 2024 $725.00M Nov 25, 2025
FY2025 Sep 30, 2023 $874.00M Nov 25, 2025
FY2024 Sep 30, 2022 $973.00M Nov 27, 2024
FY2023 Sep 30, 2021 $1.19B Nov 21, 2023
FY2022 Sep 30, 2020 $769.00M Nov 22, 2022
FY2021 Sep 30, 2019 $957.00M Nov 24, 2021
FY2020 Sep 30, 2018 $895.00M Nov 25, 2020
FY2019 Sep 30, 2017 $727.00M Nov 27, 2019
FY2018 Sep 30, 2016 $693.00M Nov 21, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $55.33B Nov 25, 2025
FY2025 Sep 30, 2024 $57.29B Nov 25, 2025
FY2024 Sep 30, 2023 $52.78B Nov 27, 2024
FY2023 Sep 30, 2022 $52.93B Nov 21, 2023
FY2022 Sep 30, 2021 $53.87B Nov 22, 2022
FY2021 Sep 30, 2020 $54.01B Nov 24, 2021
FY2020 Sep 30, 2019 $51.77B Nov 25, 2020
FY2020 Sep 30, 2018 $53.90B Nov 25, 2020
FY2019 Sep 30, 2017 $37.73B Nov 27, 2019
FY2018 Sep 30, 2016 $25.59B Nov 21, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $25.39B Nov 25, 2025
FY2025 Sep 30, 2024 $25.89B Nov 25, 2025
FY2024 Sep 30, 2023 $25.80B Nov 27, 2024
FY2023 Sep 30, 2022 $25.28B Nov 21, 2023
FY2022 Sep 30, 2021 $23.68B Nov 22, 2022
FY2021 Sep 30, 2020 $23.77B Nov 24, 2021
FY2020 Sep 30, 2019 $21.08B Nov 25, 2020
FY2019 Sep 30, 2018 $20.99B Nov 27, 2019
FY2018 Sep 30, 2017 $12.95B Nov 21, 2018
FY2017 Sep 30, 2016 $7.63B Nov 22, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $26.61B Nov 25, 2025
FY2025 Sep 30, 2024 $26.47B Nov 25, 2025
FY2025 Sep 30, 2023 $24.52B Nov 25, 2025
FY2024 Sep 30, 2022 $24.62B Nov 27, 2024
FY2023 Sep 30, 2021 $23.89B Nov 21, 2023
FY2022 Sep 30, 2020 $23.60B Nov 22, 2022
FY2021 Sep 30, 2019 $23.38B Nov 24, 2021
FY2020 Sep 30, 2018 $23.60B Nov 25, 2020
FY2019 Sep 30, 2017 $7.56B Nov 27, 2019
FY2018 Sep 30, 2016 $7.42B Nov 21, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $16.62B Nov 25, 2025
FY2025 Sep 30, 2024 $16.14B Nov 25, 2025
FY2024 Sep 30, 2023 $15.54B Nov 27, 2024
FY2023 Sep 30, 2022 $15.16B Nov 21, 2023
FY2022 Sep 30, 2021 $13.83B Nov 22, 2022
FY2021 Sep 30, 2020 $12.79B Nov 24, 2021
FY2020 Sep 30, 2019 $12.91B Nov 25, 2020
FY2019 Sep 30, 2018 $12.60B Nov 27, 2019
FY2018 Sep 30, 2017 $13.11B Nov 21, 2018
FY2017 Sep 30, 2016 $12.73B Nov 22, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $641.00M Nov 25, 2025
FY2025 Sep 30, 2024 $1.72B Nov 25, 2025
FY2024 Sep 30, 2023 $1.42B Nov 27, 2024
FY2023 Sep 30, 2022 $1.01B Nov 21, 2023
FY2022 Sep 30, 2021 $2.28B Nov 22, 2022
FY2021 Sep 30, 2020 $2.83B Nov 24, 2021
FY2020 Sep 30, 2019 $536.00M Nov 25, 2020
FY2019 Sep 30, 2018 $1.14B Nov 27, 2019
FY2018 Sep 30, 2017 $14.18B Nov 21, 2018
FY2018 Sep 30, 2016 $1.54B Nov 21, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 5 Nov 25, 2025
FY2025 Sep 30, 2024 5 Nov 25, 2025
FY2025 Sep 30, 2023 4 Nov 25, 2025
FY2024 Sep 30, 2022 5 Nov 27, 2024
FY2023 Sep 30, 2021 6 Nov 21, 2023
FY2020 Sep 30, 2020 0 Nov 25, 2020
FY2020 Jun 30, 2020 0 Nov 25, 2020
FY2020 Mar 31, 2020 0 Nov 25, 2020
FY2020 Dec 31, 2019 0 Nov 25, 2020
FY2020 Sep 30, 2019 0 Nov 25, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 5 Nov 25, 2025
FY2025 Sep 30, 2024 5 Nov 25, 2025
FY2025 Sep 30, 2023 4 Nov 25, 2025
FY2024 Sep 30, 2022 5 Nov 27, 2024
FY2023 Sep 30, 2021 6 Nov 21, 2023
FY2020 Sep 30, 2020 0 Nov 25, 2020
FY2020 Jun 30, 2020 0 Nov 25, 2020
FY2020 Mar 31, 2020 0 Nov 25, 2020
FY2020 Dec 31, 2019 0 Nov 25, 2020
FY2020 Sep 30, 2019 0 Nov 25, 2020

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $1.20B Nov 25, 2025
FY2025 Sep 30, 2024 $1.10B Nov 25, 2025
FY2025 Sep 30, 2023 $1.11B Nov 25, 2025
FY2024 Sep 30, 2022 $1.08B Nov 27, 2024
FY2023 Sep 30, 2021 $1.05B Nov 21, 2023
FY2022 Sep 30, 2020 $1.03B Nov 22, 2022
FY2021 Sep 30, 2019 $984.00M Nov 24, 2021
FY2020 Sep 30, 2018 $927.00M Nov 25, 2020
FY2019 Sep 30, 2017 $677.00M Nov 27, 2019
FY2018 Sep 30, 2016 $562.00M Nov 21, 2018